Market closedNon-fractional
Wave Life Sciences/WVE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Wave Life Sciences
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Ticker
WVE
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
Singapore, Singapore
Employees
267
Website
www.wavelifesciences.com
WVE Metrics
BasicAdvanced
$771M
Market cap
-
P/E ratio
-$0.55
EPS
-1.04
Beta
-
Dividend rate
Price and volume
Market cap
$771M
Beta
-1.04
Financial strength
Current ratio
1.186
Quick ratio
1.091
Long term debt to equity
70.944
Total debt to equity
91.796
Management effectiveness
Return on assets (TTM)
-17.95%
Return on equity (TTM)
-1,920.16%
Valuation
Price to revenue (TTM)
6.299
Price to book
30.47
Price to tangible book (TTM)
30.47
Price to free cash flow (TTM)
-5.101
Growth
Revenue change (TTM)
661.49%
Earnings per share change (TTM)
-67.81%
3-year revenue growth (CAGR)
92.15%
3-year earnings per share growth (CAGR)
-45.52%
What the Analysts think about WVE
Analyst Ratings
Majority rating from 7 analysts.
WVE Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$13M
-56.90%
Net income
-$32M
94.44%
Profit margin
-252.00%
351.13%
WVE Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.20
$0.07
-$0.15
-$0.24
-
Expected
-$0.33
-$0.18
-$0.23
-$0.21
-$0.21
Surprise
-39.66%
-139.25%
-33.82%
12.15%
-
WVE News
AllArticlesVideos
What's Going On With Wave Life Sciences Stock On Tuesday?
Benzinga·1 month ago
Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease
GlobeNewsWire·1 month ago
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Wave Life Sciences stock?
Wave Life Sciences (WVE) has a market cap of $771M as of July 27, 2024.
What is the P/E ratio for Wave Life Sciences stock?
The price to earnings (P/E) ratio for Wave Life Sciences (WVE) stock is 0 as of July 27, 2024.
Does Wave Life Sciences stock pay dividends?
No, Wave Life Sciences (WVE) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Wave Life Sciences dividend payment date?
Wave Life Sciences (WVE) stock does not pay dividends to its shareholders.
What is the beta indicator for Wave Life Sciences?
Wave Life Sciences (WVE) has a beta rating of -1.04. This means that it has an inverse relation to market volatility.
Buy or sell Wave Life Sciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.